Inactive Instrument

Press Releases TapImmune Inc Nasdaq

Equities

US8760334081

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies	Apr. 08	AQ
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results	Mar. 25	AQ
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference	Mar. 22	AQ
Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors	Mar. 13	AQ
Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601	Jan. 22	AQ
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization	Jan. 08	AQ
Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”	Dec. 21	AQ
Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse	Dec. 11	AQ
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates	Nov. 09	AQ
Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse	23-09-11	AQ
Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference	23-08-30	AQ
Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies	23-08-17	NE
Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update	23-08-14	AQ
Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program	23-08-07	AQ
Marker Therapeutics to Participate in Virtual Roundtable with Key Opinion Leaders to Discuss Clinical Landscape of CAR-T Cell Therapies on August 9, 2023	23-07-26	AQ
European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients	23-07-10	AQ
Marker Therapeutics : Unaudited Pro Forma Condensed Consolidated Financial Information - Form 8-K	23-06-30	PU
Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration	23-06-26	AQ
"Convergence of AI and Biology: Companies at the Forefront of Transformative Innovations":- IPA, MRKR, PRAX , RMED	23-06-21	AQ
Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial	23-06-12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases TapImmune Inc Nasdaq

Equities

US8760334081

Press Releases

Filters